Pay in 4 interest-free payments of $5.67 Learn more
Ships within 48 hours · Estimated delivery Sep 21 - Sep 26
Semaglutide is prescribed for: Weight loss in adult patients with an initial body mass index (BMI) of 30 kg/m2 or greater (obesity) Weight loss in adult patients with an initial body mass index (BMI) of 27 kg/m2 or greater (overweight) in the presence of at least one weight-related comorbid condition (hypertension, type 2 diabetes mellitus, or dyslipidemia) Weight loss in pediatric patients aged 12 years and older with an initial BMI at the 95th percentile or greater for age and sex (obesity) Reducing the risk of major adverse cardiovascular events (non-fatal myocardial infarction, CV death, or non-fatal stroke) in adults with cardiovascular disease and either obesity or overweight Treating noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH), formerly known as NASH, with moderate to advanced liver fibrosis (stages F2 to F3 fibrosis) in adults Patients taking semaglutide for any of these conditions, especially weight loss, are typically suggested to maintain a low-carb and low-fat diet
A GPhC-registered pharmacy: premises registration number 1110108
Run a peptide reconstitution calculator: input molecular weight, mass on the label, target concentration, and target final volume to determine the precise water volume needed
Clinical trials have shown that a daily 25mg Wegovy pill can result in an average 16.6% body weight reduction after 64 weeks compared to 2.7% with a placebo
This represents reversal of a progressive disease that can lead to cirrhosis and liver failure
US$ 20.76
US$ 25.69
US$ 22.79
US$ 29.89
US$ 22.75
